journal
MENU ▼
Read by QxMD icon Read
search

Annals of Oncology: Official Journal of the European Society for Medical Oncology

journal
https://www.readbyqxmd.com/read/28525559/first-onset-mental-disorders-after-cancer-diagnosis-and-cancer-specific-mortality-a-nationwide-cohort-study
#1
J Zhu, F Fang, A Sjölander, K Fall, H O Adami, U Valdimarsdóttir
BACKGROUND: The diagnosis of cancer is strongly associated with the risk of mental disorders even in patients with no previous history of mental disorders. Accumulating data suggest that mental distress may accelerate tumor progression. We hypothesized therefore that mental disorders after a cancer diagnosis may increase the risk of cancer-specific mortality. PATIENTS AND METHODS: We conducted a nationwide cohort study including 244,261 cancer patients diagnosed in Sweden during 2004-2009 and followed them through 2010...
May 19, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28525534/lymphocyte-density-determined-by-computational-pathology-validated-as-a-predictor-of-response-to-neoadjuvant-chemotherapy-in-breast-cancer-secondary-analysis-of-the-artemis-trial
#2
H R Ali, A Dariush, J Thomas, E Provenzano, J Dunn, L Hiller, A-L Vallier, J Abraham, T Piper, J M S Bartlett, D A Cameron, L Hayward, J D Brenton, P D P Pharoah, M Irwin, N A Walton, H M Earl, C Caldas
Background: HASH(0x3a2d8d8) Patients and methods: HASH(0x3e35870) Results: HASH(0x47570a8) Conclusions: HASH(0x39e09d8)
May 19, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28520921/can-we-trust-burnout-research
#3
R Bianchi, I S Schonfeld, E Laurent
No abstract text is available yet for this article.
May 18, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28520849/beta-blockers-and-improved-progression-free-survival-in-patients-with-advanced-her2-negative-breast-cancer-a-retrospective-analysis-of-the-rose-trio-012-study
#4
G Spera, R Fresco, H Fung, J R B Dyck, E Pituskin, I Paterson, J R Mackey
Background: Recent retrospective studies suggest that beta-adrenergic blocking drugs (BB) are associated with improved outcomes in people with a range of cancers. Although limited and discordant data suggest that BB may increase overall survival (OS) of patients with localized breast cancer (BC), there is no information on the effects of BB in women with advanced BC. Patients and Methods: To explore the association between BB use and BC outcomes, we retrospectively reviewed the ROSE/TRIO-012, a double-blinded, multinational phase III trial that randomized 1,144 patients with HER2-negative advanced BC to first-line docetaxel in combination with ramucirumab or placebo...
May 18, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28520840/assessment-of-nivolumab-benefit-risk-profile-of-a-240-mg-flat-dose-relative-to-a-3-mg-kg-dosing-regimen-in-patients-with-advanced-tumors
#5
X Zhao, S Suryawanshi, M Hruska, Y Feng, X Wang, J Shen, H E Vezina, M B McHenry, I M Waxman, A Achanta, A Bello, A Roy, S Agrawal
Background: : Nivolumab 3 mg/kg every 2 weeks (Q2W) has shown benefit versus the standard of care in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). However, flat dosing is expected to shorten preparation time and improve ease of administration. With knowledge of nivolumab safety, efficacy, and pharmacokinetics across a wide dose range in BW dosing, assessment of the benefit-risk profile of a 240-mg flat dose relative to the approved 3-mg/kg dose was approached by quantitative clinical pharmacology...
May 17, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28510616/salvage-high-dose-chemotherapy-in-female-patients-with-relapsed-refractory-germ-cell-tumors-a-retrospective-analysis-of-the-european-group-for-blood-and-marrow-transplantation-ebmt
#6
U De Giorgi, S Richard, M Badoglio, E Kanfer, J H Bourrhis, E Nicolas-Virelizier, K Vettenranta, B Lioure, S Martin, P Dreger, M K Schuler, K Thomson, E Scarpi, G Rosti, F Selle, G Mangili, F Lanza, M Bregni
Background: High-dose chemotherapy (HDC) with hematopoietic progenitor cell transplantation is a standard option for relapsed/refractory testicular germ cell tumor (GCT), but only few data have been reported in female patients with GCT. We conducted a retrospective analysis of female patients with GCT treated with HDC and registered with the European Society for Blood and Marrow Transplantation (EBMT). Patients and methods: Between 1985 and 2013, 60 registered female patients with GCT, median age 27 years (range 15-48), were treated with salvage HDC...
May 16, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28505259/immune-oncology-and-neuroendocrine-tumors
#7
A Chauhan, L Anthony
No abstract text is available yet for this article.
May 15, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28505221/combining-pi3k-and-parp-inhibitors-for-breast-and-ovarian-cancer-tratement
#8
R Condorelli, F André
No abstract text is available yet for this article.
May 15, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28505219/64cu-dota-trastuzumab-pet-imaging-for-her2-specific-primary-lesions-of-breast-cancer
#9
S Sasada, H Kurihara, T Kinoshita, M Yoshida, N Honda, T Shimoi, A Shimomura, M Yunokawa, K Yonemori, C Shimizu, A Hamada, Y Kanayama, Y Watanabe, Y Fujiwara, K Tamura
No abstract text is available yet for this article.
May 15, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28498880/a-two-arm-multicenter-phase-ii-trial-of-one-cycle-chemoselection-split-dose-docetaxel-cisplatin-and-5-fluorouracil-tpf-induction-chemotherapy-before-two-cycles-of-split-tpf-followed-by-curative-surgery-combined-with-postoperative-radiotherapy-in-patients-with
#10
J Inhestern, H Schmalenberg, A Dietz, N Rotter, G Maschmeyer, M Jungehülsing, C Grosse-Thie, T Kuhnt, M Görner, H Sudhoff, C Wittekindt, O Guntinas-Lichius
Background: : Induction chemotherapy (ICT) with docetaxel, cisplatin and fluorouracil (TPF) followed by radiotherapy is an effective treatment option for locally advanced head and neck cancer. This phase II study investigated the effectivity of a split-dose TPF ICT prior to surgery for locally advanced resectable (stage III/IVA) oral and oropharyngeal cancer. Patients and methods: : Patients received TPF split on two dosages on day 1 and 8 per cycle (30 mg/m 2 docetaxel, 40 mg/m 2 cisplatin, 2000 mg/m 2 fluorouracil per week)...
May 11, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28486692/early-results-of-a-randomized-two-by-two-factorial-phase-ii-trial-comparing-neoadjuvant-chemotherapy-with-two-and-four-courses-of-cisplatin-s-1-and-docetaxel-cisplatin-s-1-as-neoadjuvant-chemotherapy-for-locally-advanced-gastric-cancer
#11
T Aoyama, K Nishikawa, K Fujitani, K Tanabe, S Ito, T Matsui, A Miki, H Nemoto, K Sakamaki, T Fukunaga, Y Kimura, N Hirabayashi, T Yoshikawa
Neoadjuvant chemotherapy (NAC) is a promising method of improving the survival of resectable gastric cancer. Cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) are both effective against metastatic gastric cancer. This report clarified the impact of these regimens on early endpoints, including the pathological responses, chemotherapy-related toxicities, and surgical results. Patients with M0 and either T4 or T3 in case of junctional cancer or schirrhous type received 2 or 4 courses of cisplatin (60 mg/m 2 at day 8)/S-1 (80 mg/m 2 for 21 days with 1 week rest) or docetaxel (40 mg/m 2 at day 1)/cisplatin (60 mg/m 2 at day 1)/S-1 (80 mg/m 2 for 14 days with 2 weeks rest) as neoadjuvant chemotherapy...
May 9, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28486686/a-prospective-multi-centre-phase-iii-validation-study-of-azgp1-as-a-biomarker-in-localised-prostate-cancer
#12
A Y Zhang, J S Grogan, K L Mahon, K Rasiah, P Sved, D R Eisinger, J Boulas, A Vasilaris, S M Henshall, P D Stricker, J G Kench, L G Horvath
Background: HASH(0x3f784d8) Patients and methods: HASH(0x3e40058) Results: HASH(0x3ee25d8) Conclusion: HASH(0x3f44da8)
May 9, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28481969/diffuse-large-b-cell-lymphoma-dlbcl-2-versus-3-end-of-a-debate
#13
C Sarkozy, B Coiffier
No abstract text is available yet for this article.
May 8, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28481967/bevacizumab-with-or-after-chemotherapy-for-platinum-resistant-recurrent-ovarian-cancer-exploratory-analyses-of-the-aurelia-trial
#14
A Bamias, E Gibbs, C Khoon Lee, L Davies, M Dimopoulos, F Zagouri, A-S Veillard, J Kosse, A Santaballa, M R Mirza, G Tabaro, I Vergote, H Bloemendal, M Lykka, A Floquet, V Gebski, E Pujade-Lauraine
Background: In the open-label randomised phase III AURELIA trial, adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) significantly improved progression-free survival and response rate versus chemotherapy alone, but not overall survival (OS). We explored the effect of bevacizumab use after disease progression (PD) in patients randomised to chemotherapy alone. Patients and methods: In AURELIA, 361 women with PROC were randomised to chemotherapy alone or with bevacizumab...
May 8, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28475680/surgical-resection-versus-watchful-waiting-in-low-grade-gliomas
#15
A S Jakola, A J Skjulsvik, K S Myrmel, K Sjåvik, G Unsgård, S H Torp, K Aaberg, T Berg, H Y Dai, K Johnsen, R Kloster, O Solheim
Background: HASH(0x3f305d8) Material and methods: HASH(0x47dd548) Results: HASH(0x47e0e30) Conclusion: HASH(0x399bbc8)
May 5, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28475678/a-double-blind-placebo-controlled-randomized-trial-of-creatine-for-the-cancer-anorexia-weight-loss-syndrome-n02c4-an-alliance-trial
#16
A Jatoi, P D Steen, P J Atherton, D F Moore, K M Rowland, N A Le-Lindqwister, C S Adonizio, A J Jaslowski, J Sloan, C Loprinzi
BACKGROUND: Multiple pilot studies, including one in colorectal cancer patients, suggest that creatine, an amino acid derivative, augments muscle, improves strength, and thereby could palliate the cancer anorexia/weight loss syndrome. PATIENTS AND METHODS: In this randomized, double-blind, placebo-controlled trial, incurable patients with this syndrome were assigned creatine (20 gram per day load x 5 days followed by 2 grams per day orally) versus identical placebo...
May 5, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28475674/no-benefit-from-the-addition-of-anti-egfr-antibody-in-all-right-sided-metastatic-colorectal-cancer
#17
Y Sunakawa, A Tsuji, M Fujii, W Ichikawa
No abstract text is available yet for this article.
May 5, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28475671/dabrafenib-plus-trametinib-versus-dabrafenib-monotherapy-in-patients-with-metastatic-braf-v600e-k-mutant-melanoma-long-term-survival-and-safety-analysis-of-a-phase-3-study
#18
G V Long, K T Flaherty, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, C Garbe, T Jouary, A Hauschild, V Chiarion-Sileni, C Lebbe, M Mandalà, M Millward, A Arance, I Bondarenko, J B A G Haanen, J Hansson, J Utikal, V Ferraresi, P Mohr, V Probachai, D Schadendorf, P Nathan, C Robert, A Ribas, M A Davies, S R Lane, J J Legos, B Mookerjee, J-J Grob
Background: Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and trametinib versus dabrafenib monotherapy in BRAF V600E/K-mutant metastatic melanoma. This study was continued to assess 3-year landmark efficacy and safety after ≥36-month follow-up for all living patients. Patients and methods: This double-blind, phase 3 study enrolled previously untreated patients with BRAF V600E/K-mutant unresectable stage IIIC or stage IV melanoma...
May 5, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28472456/structural-and-functional-intratumor-heterogeneities-in-glioblastoma-a-spacetime-odyssey-at-single-cell-level
#19
A Idbaih
No abstract text is available yet for this article.
May 4, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28472437/romana-3-a-phase-3-safety-extension-study-of-anamorelin-in-advanced-non-small-cell-lung-cancer-nsclc-patients-with-cachexia
#20
D Currow, J S Temel, A Abernethy, J Milanowski, J Friend, K C Fearon
Background: HASH(0x3a3e480) Patients and methods: HASH(0x47fcc30) Results: HASH(0x3f18898) Conclusion: HASH(0x481a3f8) Clinical trial registration numbers: HASH(0x3e169c0)
May 4, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
journal
journal
30452
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"